

Table 2.6. Randomized clinical trials of chemopreventive use of tamoxifen and incident breast cancer

Reference, country	No. of patients and treatment		Dose of tamoxifen (mg/day)	Duration (years)	Median follow-up (years)	Number (rate/1000) contralateral breast cancers	Risk ratio (95% CI)	Comments	
Cuzick et al. (2003), (International)	14 214	Tamoxifen	20	5–8	10	289	0.62 (0.54–0.72)	Overview analysis of four chemoprevention trials.	
	14 192	Placebo				465			
						ER +ve	135		0.52 (0.42–0.62)
						ER –ve	267		
			88	1.22 (0.89–1.67)					
			72						
Fisher et al., (2005) United States and Canada	6597	Tamoxifen	20	1–5	7	Overall	0.57 (0.46–0.70)	Recruitment of high-risk women 1992–1997. Intervention stopped in 1998 as endpoint reached.	
	6610	Placebo				145			
						ER +ve	250		
						ER –ve	182		0.38 (0.28–0.50)
							70		
							56		1.31 (0.86–2.01)
			42						